The results demonstrated that treatment with 10 μM Ivosidenib reduced the expression of ALDH1A1 and SOX2 in ovarian cancer cells compared to the DMSO control group [Supplementary Figure 5C]. This evidence concerns the gene ALDH1A1 and ovarian cancer.